-
Mashup Score: 1CEU 2023 | September 21-23, 2023 - 9 month(s) ago
Join us on September 21-23 for the Clinical Endocrinology Update (CEU) 2023 online meeting.
Source: ceu2023.endocrine.orgCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0OP0246 ROMOSOZUMAB VERSUS DENOSUMAB IN HIGH-RISK PATIENTS WITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS: A PILOT RANDOMIZED CONTROLLED TRIAL - 11 month(s) ago
Objectives To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients with glucocorticoid (GC)-induced osteoporosis (GIOP). Methods Design: A pilot open randomized controlled trial. Method: Adult patients (≥18 years) who were receiving daily prednisolone dose of ≥5mg/day for ≥12 months and had moderate/high risk of osteoporotic fracture (a history of…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
#Romosozumab superior to #denosumab in raising #spine BMD in glucocorticoid users with high #fracture risk ➡️Romosozumab may offer new treatment option in #glucocorticoid induced #osteoporosis By Chi Chiu Mok #EULAR2023 OP0246 👉🏼https://t.co/VfjYGDVJcp Via @ARD_BMJ https://t.co/O2zlBgjZCz
-
-
Mashup Score: 0Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone - Nature Reviews Rheumatology - 12 month(s) ago
Long-term treatment with the anti-resorptive drug denosumab results in a continuous gain in bone mineral density, whereas denosumab withdrawal results in a transient overshoot in bone turnover, with rapid bone loss. This Perspective explores the potential mechanisms underlying these effects.
Source: NatureCategories: Latest Headlines, RheumatologyTweet-
#MayIssue | This #Perspective explores mechanisms whereby long-term treatment with the anti-resorptive #denosumab results in continuous gain in #bone mineral density, and withdrawal results in transient overshoot in bone turnover, with rapid bone loss. https://t.co/gTGgG1rT8r https://t.co/blMLnETvKC
-
-
Mashup Score: 0Nature Reviews Rheumatology - Volume 19 Issue 5, May 2023 - 12 month(s) ago
Inspired by the Review on p265.
Source: NatureCategories: Latest Headlines, RheumatologyTweet-
Our #MayIssue is out now! Featuring the involvement of vitamin D in #rheumatic disease and #COVID-19, #genetics and #epigenetics of primary #Sjögren syndrome, and mechanisms in long-term use and withdrawal of #denosumab https://t.co/ysBwQtyx5j https://t.co/eh2tnlP298
-
-
Mashup Score: 0Bisphosphates and Denosumab in Advanced Prostate Cancer - 1 year(s) ago
A summary of the evidence regarding bisphosphate and denosumab therapy and the positive impact that bone-protective agents can have on patients.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
GU Oncology Now Associate Editor @AkhilASaji gives an overview of the evidence regarding #bisphosphate and #denosumab therapy, as well as the positive impact that bone-protective agents can have on patients with advanced #prostatecancer. Learn more: https://t.co/RZyQbe8t9m https://t.co/et7QlwbIGu
-
-
Mashup Score: 0
Improvements in GUSS, a validated tool developed to identify changes in hand osteoarthritis over time, were higher in the denosumab group when compared with placebo and the development of new erosive joints was significantly lower at week 48.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Improvements in GUSS, a validated tool developed to identify changes in hand #osteoarthritis over time, were higher in the #denosumab group when compared with placebo and the development of new erosive joints was significantly lower at week 48. https://t.co/CuUpew2pXm
-
-
Mashup Score: 0
Improvements in GUSS, a validated tool developed to identify changes in hand osteoarthritis over time, were higher in the denosumab group when compared with placebo and the development of new erosive joints was significantly lower at week 48.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Improvements in GUSS, a validated tool developed to identify changes in hand #osteoarthritis over time, were higher in the #denosumab group when compared with placebo and the development of new erosive joints was significantly lower at week 48. https://t.co/Lr9cuqWGmx
-
-
Mashup Score: 0Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Managing bone health after #denosumab cessation is a common challenge in patients with #cancer. This commentary reviews the evidence on the efficacy and safety of various antiresorptive agents in mitigating the "rebound phenomenon”. @YMMelodyCheung https://t.co/tJukxKWM9i https://t.co/ueWeyq38k4
-
-
Mashup Score: 0Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone - 2 year(s) ago
A 41-year-old man presented with a 2-month history of progressive vision loss and headaches. MRI revealed a large sellar tumour with suprasellar extension, which was deemed a probable pituitary macroadenoma (figure A, B). The patient underwent transsphenoidal surgery because of visual field defects and headaches. Histological analysis after surgery revealed a giant cell tumour of bone (GCTB) and…
Categories: Endocrinology, Latest HeadlinesTweet-
Clinical Picture: #Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell #tumour of #bone https://t.co/X0mUgblXIZ #FREE to read https://t.co/PgMxcLaqKd
-
-
Mashup Score: 1EFL020 - Zoledronate to Maintain BMD Gains After Denosumab - 2 year(s) ago
Episode 20 of Endocrine Feedback Loop features our host, Dr. Chase Hendrickson, and two bone metabolism experts, Dr. Amal Shibli-Rahhal and Dr. John Bilezikian, as they discuss a recent article from JCEM focused on maintaining bone density following medication therapy.
Source: www.endocrine.orgCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: Zoledronate to Maintain BMD Gains After Denosumab | Listen to Amal Shibli-Rahhal, MD and John Bilezikian, MD, PhD (hon) as they discuss #zoledronate to maintain BMD gains after #Denosumab in episode 20 of Endocrine Feedback Loop: https://t.co/GCyFlPoUir
-
Enhance Your Bone Care at #CEU2023 | Learn about cutting-edge advances for diagnosing and managing #bonediseases. Our sessions feature topical areas covering #denosumab discontinuation, #hypercalcemia, skeletal health management, and more: https://t.co/eiqcnkqXU0 #bone #calcium https://t.co/vPxkAeUwzn